• Latest
  • Trending
US Drug Regulatory Body Approves Treatment for Ebola

US Drug Regulatory Body Approves Treatment for Ebola

December 22, 2020
ARISE XCHANGE

ARISE XCHANGE

January 22, 2021
Ethiopia Drops Gun Charges Against Media Mogul Jawar Mohammed

Ethiopia Drops Gun Charges Against Media Mogul Jawar Mohammed

January 22, 2021
Court Orders Nigerian Senator Be Remanded Over Former Pension Boss Disappearance

Nigeria’s Supreme Court Dismisses Appeal By Abacha’s Family to Access Frozen Foreign Accounts

January 22, 2021
Trump’s Trial for ‘Inciting Insurrection’ to Start Monday

Trump’s Trial for ‘Inciting Insurrection’ to Start Monday

January 22, 2021
Russia Welcomes US Proposal to Extend Nuclear Treaty

Russia Welcomes US Proposal to Extend Nuclear Treaty

January 22, 2021
Twin Suicide Bombings Kill At Least 23 in Iraqi Capital Baghdad

Islamic State Claims Responsibility for Twin Suicide Blasts in Baghdad

January 22, 2021
Japan Vaccination Uncertainty Casts Doubts Over Olympics    

Japan Vaccination Uncertainty Casts Doubts Over Olympics  

January 22, 2021
Comedian Dave Chappelle Tests Positive for Covid-19, Shows Canceled

Comedian Dave Chappelle Tests Positive for Covid-19, Shows Canceled

January 22, 2021
Germany’s Covid-19 Death Toll Tops 50,000

Germany’s Covid-19 Death Toll Tops 50,000

January 22, 2021
UN Expresses Concern Over ‘Disturbing Rape Reports in Tigray’

UN Expresses Concern Over ‘Disturbing Rape Reports in Tigray’

January 22, 2021

Nigeria Can Defeat Kidnappings Within Three Months Using Drones, Says Surveillance Expert

January 22, 2021

Nigeria: Former Electoral Commission Boss Jega Calls for Scrap of ‘Unnecessary’ Federal Ministries

January 22, 2021
ARISE Newsday

ARISE Newsday

January 22, 2021
UN Expresses Concern Over ‘Disturbing Rape Reports in Tigray’

UN Expresses Concern Over ‘Disturbing Rape Reports in Tigray’

January 22, 2021
#Watch: I Proposed That We Send Goodluck Jonathan to Help Trump Come to Terms With Losing Election – Wole Soyinka

Soyinka: ‘No Difference’ Between Trump and Uganda’s Museveni

January 22, 2021
#Watch: I Proposed That We Send Goodluck Jonathan to Help Trump Come to Terms With Losing Election – Wole Soyinka

Trumps’s Sole Agenda Was to Dismantle Obama’s Legacy

January 22, 2021
Global Business Report

Global Business Report

January 22, 2021

Morning Show

January 22, 2021
Next James Bond Film Delayed for Third Time Due to Covid-19

Next James Bond Film Delayed for Third Time Due to Covid-19

January 22, 2021
Restructuring Alone Can’t Solve Nigeria’s Problems, Former President Jonathan Says

Restructuring Alone Can’t Solve Nigeria’s Problems, Former President Jonathan Says

January 22, 2021
Bitcoin Breaks Above $20,000 for First Time

Bitcoin Slide Continues, Heads for Worst Week Since March 2020

January 22, 2021
Nigerian Nurses Raise the Alarm over Inadequate Medical Personnel for Covid-19 Vaccination

Nigerian Nurses Raise the Alarm over Inadequate Medical Personnel for Covid-19 Vaccination

January 22, 2021
Chinese Rescuers Hope to Drill Shaft to Free Trapped Gold Miners

Trapped China Gold Miners Have to Wait 15 Days for Rescue

January 22, 2021
Finance Minister Says Nigeria Taking $750m World Bank Loan on Behalf of States, Blames Transport Costs for Inflation

Nigeria Approves $17m for 38 New Oxygen Plants Nationwide

January 22, 2021
Buhari Approves Another Five-year Term for Nigeria Ports Boss Hadiza Bala Usman

Stakeholders Hail Reappointment of Bala-Usman as Nigeria Ports Boss

January 22, 2021
Court Sets Aside Death Sentence on Kano Singer, Orders Retrial   

Court Sets Aside Death Sentence on Kano Singer, Orders Retrial  

January 22, 2021
Nigeria: Zamfara Governor Denies Ruling Party’s Accusation of Sponsoring Bandits

Nigeria: Zamfara Governor Accuses Traditional Rulers of Sabotaging Peace Efforts

January 22, 2021
Google Threatens to Withdraw Search Engine from Australia

Google Threatens to Withdraw Search Engine from Australia

January 22, 2021
US House Lawmakers Set to Impeach Trump For Historic 2nd Time

Republicans Seek Delay Until February to Give Trump ‘Fair’ Impeachment Trial

January 22, 2021
#EndSARS: Buhari Promises Extensive Police Reforms

Buhari Demands Stricter Measures to Tackle Tax Evasion in Nigeria

January 22, 2021
en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish
No Result
View All Result
Saturday, January 23, 2021
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • US ELECTION
  • BUSINESS
  • Politics
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • US ELECTION
  • BUSINESS
  • Politics
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
No Result
View All Result
Arise News
No Result
View All Result
Home Health

US Drug Regulatory Body Approves Treatment for Ebola

December 22, 2020
Reading Time: 3min
0 0
0
US Drug Regulatory Body Approves Treatment for Ebola
Share on FacebookShare on Twitter

The US Food and Drug Administration has approved antibody Ebanga for the treatment of the Ebolavirus infection (Zaire ebolavirus) in adults and children, 44 years after the deadly disease was first discovered.

Zaire ebolavirus is one of four Ebolavirus species that can cause a potentially fatal human disease. It is transmitted through blood, body fluids, and tissues of infected people or wild animals, and through surfaces and materials, such as bedding and clothing, contaminated with these fluids.

Ebanga, human monoclonal antibody, blocks binding of the virus to the cell receptor, preventing its entry into the cell.

During an Ebola outbreak in the Democratic Republic of the Congo in 2018-2019, Ebanga was evaluated in a clinical trial, called the PALM trial, which was led by the US National Institutes of Health and the DRC’s Institut National de Recherche Biomédicale with contributions from several other international organizations and agencies.

In the PALM trial, the safety and efficacy of Ebanga was evaluated in a multi-center, open-label, randomized controlled trial. 174 participants (120 adults and 54 pediatric patients) with confirmed Ebolavirus infection received Ebanga intravenously, and 168 participants (135 adults and 33 pediatric patients) received an investigational control.

The primary analysis population was all patients who were randomized and concurrently eligible to receive either Ebanga or the investigational control during the same time period of the trial.

Of the 174 patients who received Ebanga, 35.1% died after 28 days, compared to 49.4% of the 168 patients who received a control.

The most common symptoms experienced while receiving Ebanga include: fever, diarrhea, vomiting, low blood pressure and chills. However, these are also common symptoms of Ebolavirus infection.

Patients who receive Ebanga have been advised to avoid the concurrent administration of a live virus vaccine against Ebolavirus. There is the potential for Ebanga to inhibit replication of a live vaccine virus and possibly reduce the efficacy of this vaccine.

Ebanga was granted an Orphan Drug designation, which provides incentives to assist and encourage drug development for rare diseases.

Additionally, the agency granted Ebanga a Breakthrough Therapy designation, a process designed to expedite the development and review of drugs that are intended to treat a serious condition.

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2020 Arise News - Part of the Arise Media Group.

No Result
View All Result
  • HOME
  • Breaking
  • Global
  • Regional
  • US ELECTION
  • BUSINESS
  • Politics
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates

© 2020 Arise News - Part of the Arise Media Group.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist